The blockade of the interaction of secreted EDIL3 with the integrin αVβ3 by cilengitide restored sensitivity to paclitaxel, and reverted the mesenchymal phenotype in paclitaxel-resistant cancer cells. This evidence concerns the gene EDIL3 and cancer.